Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

The authors would like to correct the errors in Table 1 and text in the published article. The correct table and the text should read as below. In Table 1, the numbers for the intent-to-treat population for biliary stent and previous Whipple procedure were erroneously switched. Table 1 should appear as below. The corresponding text for Table 1 under the Baseline Characteristics heading in the Results section should read, ‘‘Fewer patients in the Canadian cohort had a KPS of 100 than in the ITT population,’’ i.e., removing ‘‘or previous Whipple procedure’’ from the original sentence which read ‘‘Fewer patients in the Canadian cohort had a KPS of 100 or previous Whipple procedure than in the ITT population.’’ Under the Statistical Analyses section, the second-to-last sentence reads ‘‘A nonstratified log-rank test was PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.’’ It should read ‘‘A stratified log-rank test was used to compare PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.’’ In the Discussion (last paragraph beginning at the bottom of page 756), the sentence reads, ‘‘Health Canada has approved nab-P ? Gem and FOLFIRINOX for the treatment of patients with The online version of the original article can be found under doi:10.1007/s12325-016-0327-4.